Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 20-04-2018

Legal Publication Date:- 17-05-2018

Journal Code (180517)

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

16-04-2018		
245/2018	JUBILANT DRAXIMAGE INC. CANADA Ottawa Heart Institute Research Corporation CANADA (Priority 14-04-2017 US)	"RUBIDIUM ELUTION SYSTEM"
246/2018	GlaxoSmithKline Intellectual Property Development Limited United Kingdom (Priority 18-04-2017 UK)	"CHEMICAL COMPOUNDS"
247/2018	Nouman Idris Butt Mrs. Michiko Yoshida (Mariam Siddiqa) Mr. Riaz-Ud-Din Sheikh Sialkot – Pakistan	"A COMPARTMENTALIZED FORCE ABSORBENT BALL PANEL AND METHOD OF MANUFACTURING OF THE SAME"
17-04-2018		
248/2018	Muhammad Umer Ishtiaq Gujranwala – Pakistan	"PROTECTED LIFE"
249/2018	Muhammad Umer Ishtiaq Gujranwala – Pakistan	"MAGNO BIN"
250/2018	QINGDAO HAIER AIR CONDITIONER GENERAL CORP., LTD., China (Priority 22-05-2017 CN)	"METHOD FOR CONTROLLING AIR CONDITIONER USING UNINTERRUPTIBLE POWER SUPPLY AND AIR CONDITIONER"

251/2018	NEUROCRINE BIOSCIENCES, INC., USA (Priority 19-04-2017 US)	"VMAT2 INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO"
252/2018	1. **MUHAMMAD WASEEQ UR RAHMAN SIDDIQUI** **Islamabad** 2. **SYED SAJJAD RAZA** **Islamabad** 3. **UMAIR ANWAR** **Wah Cantt.** 4. **DR. MEHR NIGAR** **Islamabad** 5. **MUHAMMAD AWAIS** **Lahore** 6. **MUHAMMAD ZUBAIR** **Rawalpindi** 7. **HARIS SHAHPAL MEHMOOD** **Islamabad – Pakistan** 8. **ISHTIAQ HUSSAIN** **Islamabad**	**"Design and Fabrication of Solid Waste Plastic to Liquid Fuel Plant"**
253/2018	Joint Stock Company "BIOCAD" Russia (Priority 17-04-2017 Russia)	"ANTI-PD-L1 MONOCLONAL ANTIBODY"
254/2018	Breakthrough Technologies, LLC USA (Priority 18-04-2017 US)	"SULPUR PRODUCTION"
255/2018	Vifor (International) AG Switszerland (Priority 18-04-2017 EP)	"NOVEL FERROPORTIN-INHIBITOR SALTS"
18-04-2018		
256/2018	1. **Zahid Gul Khan** 2. **Muhammad Ahmed**	**"Design and development of the university of Haripor (UOH) Gas Safety**

	3. Dr. Abid Farid **4. Muhammad Junaid** **Haripur – Pakistan**	**System"**
257/2018	**1. Muhammad Ahmed** **2. Zahid Gul Khan** **3. Dr. Abid Farid** **4. Muhammad Junaid** **Haripur – Pakistan**	**"Design and development of novel Walk through security gate"**
258/2018	Dr. Emad Uddin Mr. Muhammad Zulfiqar Mr. Zeeshan Ejaz Dr. Muhammad Sajid Dr. Aamir Mubashar Dr. Samiur Rahman Shah **NUST** Islamabad - Pakistan	"Indirect Evaporative Cooler Working on Maisotsenko Cycle"
259/2018	Dr. Emad Uddin Dr. Nabeel Arif Dr. Aamir Mubashar **NUST** Islamabad - Pakistan	"Perforated Armour Plate "
260/2018	BAYER AKIENGESELLSCHAFT Germany (Priority 24-04-2017 EP)	"FUSED BICYCLE HETEROCYCLE DERIVATIVES AS PESTICIDES"
261/2018	ELI LILLY AND COMPANY USA (Priority 03-05-2017 US)	"ANTI-CGPR/ANTI-IL-23 BISPECIFIC ANTIBODIES AND USE THEREOF"
19-04-2018		
262/2018	Meiji Co., Ltd., Japan (Priority 20-04-2017 JP)	"AGENT FOR PROMOTING LIPID ABSORPTION"

263/2018	Novartis AG Switzerland (Priority 20-04-2017 US)	"SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS"
264/2018	Mrs. HIRA ASIM HUSAIN Islamabad - Pakistan	"CDFR (Custom Designed Face Recognition)
265/2018	H/Dr. Muhammad Nadeem Sarosh Nadeem Islamabad – Pakistan	"Glorious Skin Cream"
20-04-2018		
266/2018	Gilead Sciences, Inc., USA (Priority 20-04-2017 US)	"PD-1/PD-L1 INHIBITORS"
267/2018	Gilead Sciences, Inc., USA (Priority 20-04-2017 US)	"PD-1/PD-L1 INHIBITORS"
268/2018	Gilead Sciences, Inc., USA (Priority 20-04-2017 US)	"PD-1/PD-L1 INHIBITORS"
269/2018	BONUMOSE LLC USA	"ENZYMATIC PRODUCTION OF D-ALLULOSE"
270/2018	Otsuka Pharmaceutical Co., Ltd., Japan (Priority 20-04-2017 UK)	"A PHARMACEUTICAL COMPOUND"
271/2018	Mrs. HIRA ASIM HUSAIN Islamabad - Pakistan	"IKL-CR:Tech" (Isb, Kar & Lhr-Car Recognition: Technology"

272/2018	GUL MKUHAMMAD KHAN Peshawar – Pakistan	"Transfocure for transformer and generator monitoring with electricity management and controlling technical/administrative losses"

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be as certained on application to the office.

10/2006	PFIZER PRODUCTS INC. U.S.A.	"HETEROAROMATIC COMPOUND AS PDE10 INHIBITOR AND PREPARATION THEREOF" C07D401/14. **142771** The present invention relates to heteroaromatic compound of formula I:  wherein the variables are defined in the claims and specification. The present invention further provides preparation

		and pharmaceutical composition of said compound. The compound of present invention serves as effective phosphodiesterase (PDE) inhibitor and is useful for treating certain central nervous system (CNS) or other disorders.
173/ 2006	Recordati Ireland Limited Ireland.	" AMORPHOUS LERCANIDIPINE HYDROCHLORIDE" C07D211/09, A61P9/12 & A61K31/435. **142772** The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further provides methods of preparing substantially pure amorphous lercanidipine, and pharmaceutical compositions containing the substantially pure amorphous lercanidipine.
26/ 2011	1) Shahina Fayyaz 2)Tabassum Ara Khanum. Pakistan.	" A process of preparation of a bio-pesticide for honey and stored grain pests from Oscheius niazii, a new entomopathogenic nematodes." A01N25/00, A01N25/08 & A01N65/00. **142773** This invention relates to a process of preparation of a bio-pesticide for honey and stored grain pests from Oscheius niazi. This process comprising steps of dissolving 300-500 nematodes / ml of a new entomopathogenic nematode species Oscheius niazii / ml suspension in 1 ml water by pouring directly to the Galleria mellonella larvae (pest of honey) and Tribolium castaneum (larvae and adult) (pest of stored grain) on Petridish assay. Nematodes were able to reproduce on G. mellonella larvae and T. castaneum (larvae and adult) at 25 ±2 °C after 24-32h. The effect of

		Oscheius niazii in controlling G. mellonella larvae and T. castaneum (larvae and adult) can reach over 88, 90 and 77.6%,respectively.
184/ 2012	Sanofi-Aventis Deutschland GmbH Germany	"DRUG DELIVERY DEVICE COMPRISING A RESETTABLE DOSE SETTING MECHANISM" A61M5/24. **142774** A resettable drug delivery device (1) is provided comprising a body (9, 11), a cartridge holder (7) for receiving a cartridge (8), and means (13, 14, 17, 18) for releasably coupling the cartridge holder (7) to the body (9, 11) or the dose setting mechanism. During an initial rotational coupling movement of the cartridge holder (7) relative to the body (9, 11) or the dose setting mechanism the cartridge holder (7) is caused to move in a first axial direction relative to the body (9, 11) or the dose setting mechanism and during a continued rotational coupling movement of the cartridge holder (7) relative to the body (9, 11) or the dose setting mechanism the cartridge holder (7) is caused to move in a second, contrary axial direction.
451/ 2012	ELI LILLY AND COMPANY U.S.A.	" NOTCH PATHWAY SIGNALING INHIBITOR COMPOUND" C07K5/06, A61K38/05, C07D401/04, A61P35/00 & A61P35/02. **142775** The present invention provides a compound of the structure: 

		or a hydrate thereof, and a pharmaceutical composition containing said compound, or a hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer.
646/ 2012	Novartis AG Switzerland	" FUSION PROTEIN COMPRISING AN FGF2I VARIANT AND AN FC REGION FOR TREATING METABOLIC DISORDERS" A61K47/48 & C07K14/50. **142776** The invention relates to the identification of a fusion protein comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed is application of said protein in treating FGF21-associated disorders, including metabolic conditions.
361/ 2013	IRM LLC Bermuda	"A NOVEL COMPOUND FOR MODULATING EGFR ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF" C07D413/04, C07D403/14 & A16K31/4439. **142777** The present invention provides a compound having Formula (5):  (5) wherein the variables are as defined in the claims and specification. The present invention further provides a

		pharmaceutical composition comprising above said compound and a pharmaceutically acceptable carrier. The compound of present invention is useful for modulating EGFR activity and for treating, ameliorating or preventing a condition associated with abnormal or deregulated EGFR activity.
456/ 2013	PFIZER PRODUCTS INC. U.S.A.	"PHARMACEUTICALLY ACCEPTABLE SALT OF HETEROAROMATIC COMPOUND AS PDE10 INHIBITOR AND PREPARATION THEREOF" C07D401/14, C07D413/14 , A61K31/14 & A61P25/18. **142778** The invention pertains to pharmaceutically acceptable salt of heteroaromatic compound of formula I:  I that serves as effective phosphodiesterase (PDE) inhibitor. In particular, the invention relates to said salt of compound which is selective inhibitor of PDE10. The invention also relates to intermediates for preparation of the said salt of compound; pharmaceutical compositions comprising the said salt of compound; and the use of the said salt of compound in a method for treating certain central nervous system (CNS) or other disorders.
789/ 2013	ELI LILLY AND COMPANY U.S.A.	"6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-lh-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2¬-one as a tarp(transmembrane AMPA receptor regulatory proteins)-gamma 8 dependent AMPA(a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic

		acid) receptor antagonist" C07D417/14, A61K31/4439 & A61K45/06. **142779** The present invention is directed to a compound 6-((S)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1 H-pyrazol-3 -yl} -ethyl)-3H- 1 ,3-benzothiazol-2-one, having structural formula;  The present invention further provides a pharmaceutical composition comprising above said compound and one or more pharmaceutically acceptable carriers, diluents, or excipients. The compound of present invention is a TARP (transmembrane AMPA receptor regulatory proteins)- gamma 8 dependent AMPA (a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid) receptor antagonist which is therapeutically effective in the treatment of seizures in a mammal with epilepsy.
237/ 2014	DOW AGROSCIENCES LLC. U.S.A.	"HERBICIDAL COMPOUND COMPRISING 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATE AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATE" A01N43/40 & A01N43/54. **142780** The present invention relates to 4-amino-6-(4-substituted-phenyl)-picolinic acid, and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylic

		acid, a compound of Formula (I):  (I) wherein X, R^1, R^2, R^3, R^4, Ar, N, O as defined herein, composition comprising them, and their use as herbicide.
340/ 2014	CHIESI FARMACEUTICI S.p.A., Italy.	"PARTICLE SIZE REDUCTION OF AN ANTIMUSCARINIC COMPOUND" A61K9/00 & A61K9/14. **142781** The present invention relates to a process for preparing a crystalline micronised particulate of a glycopyrronium salt. The process involves suspending the drug in a water immiscible anti-solvent in which the drug has little or no solubility and micronizing the suspension. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.
421/ 2014	CHIESI FARMACEUTICI S.p.A., Italy.	"KINASE INHIBITOR" C07D471/04, A61K31/519 & A61P29/00. **142782** This invention relates to compound of formula (I)  (I)

		wherein W, Y, R^1, R^2, N, H, A, O are as defined therein; and composition that are p38 MAPK inhibitor, useful as anti- inflammatory agent in the treatment of, inter alia, diseases of the respiratory tract.
129/ 2015	ELI LILLY AND COMPANY U.S.A.	"AN ANTIBODY THAT BINDS TO HUMAN IL-21 AND PHARMACEUTICAL COMPOSITION THEREOF" C07K16/24. **142783** The present invention relates to engineered, humanized antibody that has high binding affinity for and neutralizes human IL-21. The present invention further provides a pharmaceutical composition comprising the above said antibody and a pharmaceutically acceptable excipient and method for recombinantly producing the antibody. The antibody of present invention is useful to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions.
138/ 2015	CHIESI FARMACEUTICI S.p.A., Italy.	" MELATONIN-BASED FORMULATION FOR PARENTERAL ADMINISTRATION" A61K9/14,A61K9/19, A61K9/51, A61K31/4045 & A61P43/00. **142784** The present invention relates to a melatonin formulation suitable for parenteral administration to neonates. In particular, the present invention relates to a pharmaceutical formulation comprising nanoparticles of melatonin for use for the treatment of neonatal brain injury. The formulation could be in form of powder to be reconstituted before use or in form of ready-to-use suspension in a proper aqueous vehicle.

		The invention is also directed to a process of its preparation.
710/ 2015	1)Asghari Bano 2) Naeem Khan Pakistan.	"Novel methods for the revegetation of deserted lands" C05F11/08. **142785** The present disclosure deals with a process for the revegetation of deserted land and sandy soil/arid soil. The process involves formulation and application of biofertilizer named Rhizoaab mixed with PGPR produced Exopolysaccharides and Plant growth regulator(s) The step comprises consortium preparation of 3 plant growth promoting rhizobacteria (PGPR) Planomicrobium chinense, Bacillus cereus and Pseudomonas fluorescence isolated from desert land of Karak from roots of peanut grown in sandy soil mixed with a carrier of maize straw /sugar cane husk or liquid inocula of above mentioned PGPR strains mixed in equal amounts. The process can be improved by the combined application of plant growth regulators (PGR), named Salicylic acid (SA) and Putrescine (Put) applied foliarly at early vegetative phase of the plant. The combined treatment improves defense system of the plant against diseases. The PGR can be applied mixed with Exopolysaccharide of the PGPR isolated from and region. The said biofertilizer / bioinoculat can be used to soak the seeds prior to sowing or also added to soil with irrigation water, can be used as broadcast to soil prior to sowing or the aqueous suspension of Rhizoaab or liquid inocula can be used for root dipping of the seedling prior to transplanting. The biofertilizer significantly increased the growth and yield in the deserted land of Khushab, Where soil is sandy. The PGPR used in Biofertilizer or as both culture produced exopolysaccharide that formed soil aggregation around roots of the plants and increase soil moisture by 30% of the control. The relative water content (80%) of leaves and root fresh (80%) and dry weight (68%) were higher in the biofertilizer

		inoculated plants. The bioinoculant biofertilizer significantly increased leaf chlorophyll content (43%), proline (29%), Protein (43%), and sugar (38%) as compared to control. Integrative use of effective PGPR strains (in consortium) along with SA or with Exopolysaccharides appears to be an effective eco-friendly approach to combat desertification and revegetate the desert lands.
732/ 2016	ELI LILLY AND COMPANY U.S.A.	"Pharmaceutically acceptable salt of 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp(transmembrane ampa receptor regulatory proteins)-gamma 8 dependent ampa(α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid) receptor antagonist" C07D417/14,A61K31/4439 & A61K45/06. **142786** The present invention is directed to a pharmaceutically acceptable salt of a compound of the formula;  The present invention further provides a pharmaceutical composition comprising above said pharmaceutically acceptable salt of a compound and one or more pharmaceutically acceptable carriers, diluents, or excipients. The pharmaceutically acceptable salt of a compound of present invention is a TARP (transmembrane AMPA receptor regulatory proteins)-gamma 8 dependent AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid) receptor antagonist which is therapeutically effective in the treatment

		of seizures in a mammal with epilepsy.
176/ 2017	DOW AGROSCIENCES LLC. U.S.A.	"HERBICIDAL N-OXIDE OR AGRICULTURALLY ACCEPTABLE SALT OF 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATE AND 6-AMINO-2-(4-SUBSTITUTED-PHIENYL)-PYRIMIDINE-4-CARBOXYLATE" A01N43/46 & A01N43/54. **142787** The present invention relates to a N-oxide or agriculturally acceptable salt of 4-amino-6-(4-substituted-phenyl)-picolinic acid, and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylic acid, a compound of Formula (I):  (I) wherein X, R^1, R^2, R^3, R^4, Ar, N, O as defined herein, composition comprising them, and their use as herbicide.
267/ 2017	Qurat ul Ain Khan Pakistan.	"SYSTEMS FOR VERIFYING ORIGINALITY OF A PRODUCT" G06Q10/06 **142788** Various aspects of the invention provide systems and methods for verifying the originality of a product. One aspect of the invention provides a

		method of verifying the authenticity of a product through a plurality of stages of a supply chain. The method includes providing a product having a plurality of distinct hidden unique identifier to the product and at each of at least one of the plurality of stages of the supply chain, verifying the authenticity of a revealed unique identifier, thereby verifying the authenticity of the product. Another aspect of the invention provides a tamper-evident package including a plurality of distinct hidden unique identifiers. The plurality of distinct unique identifiers can be selectively revealed.Other aspect of the invention provides a system including: a Self-evident package; and a unique identifier usable to verify the originality of the product, the unique identifier contained within the Self-evident package. The unique identifier cannot be detected from outside of the self-evident package without demonstrating evidence of tampering.

CORRIGENDUM

In the patents' journal issued dated **03-05-2018,** under the heading **"APPLICATION ACCEPTED"**. The following correction are as under :-

APPLICATION NO. 851/2011
(Change in Patent No. only)

For : 142647

Read : 142747

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Applicant
18/04/2018			
1.	19272	Hot Pot (Class-Nill)	M/s. Zulquirnain Corporation
2.	19273	ICE-IT (Class-01)	Aqsa Ajmal, Muslim and Amsal Mumtaz
3.	19274	PECO (Class-01)	Ume Hani Akhtar, Muslim and Amsal Mumtaz
4.	19275	Dipcoat (Class-01)	Alishba Shakoor and Khadija Zia
5.	19276	Miraki (Class-01)	Rida Hassnain and Khadija Zia
6.	19277	Corrugated Potato Cutter (Class-01)	Azka Athar and Khadija Zia
7.	19278	Liquit (Class-01)	Hiffza Yaqoob and Khadija Zia
8.	19279	Presso (Class-01)	Mehreen Hasan and Amsal Mumtaz
9.	19280	Ambidexterous Grinder (Class-01)	Rabeea Mughees and Khadija Zia
10.	19281	Shear (Class-01)	Hina Khush and Khadija Zia
11.	19282	Verdure (Class-01)	Alieha Batool, and Khadija Zia
12.	19283	Electric powered wheel (Class-01)	Muhammad Haroon Waseem, Syed Muhammad Maaz,Saif Ahmed Khan and Ali Arshad
13.	19284	Sleeping unit for PTSD patients (Class-01)	Talha Shahzad, Muslim, Adult,Pakistani and Rao Shahzaib Ali Khan, Muslim,Adult,Pakistani
14.	19285	Wee-Vast (Class-01)	Muhammad Huzaifa and Khadija Zia
15.	19286	Twister (Class-01)	Hira Ejaz, and Khadija Zia
16.	19287	De Yolker (Class-01)	Cybil Mary Braganza and Khadija Zia
17.	19288	Divers Cutting Board (Class-01)	Lyba Naveed and Khadija Zia
18.	19289	Butter Separator (Class-01)	Saniya Tariq and Amsal Mumtaz
19.	19290	Chai-making Appliance (Class-01)	Durr E Shehwar and Syed Ahmed Jawwad Zaidi
20.	19291	Electric Supercar (Class-01)	M Abdul Mannan, and Rao Shahzaib Ali Khan
21.	19292	Spinnet (Class-01)	Batool Fatima and Khadija

			Zia
22.	19293	Dinning table solution (Class-01)	Naima Baqar and Rao Shahzaib Ali Khan
23.	19294	Fingertips (Class-01)	Badar Khan and Khadija Zia
24.	19295	Ankle Foot Orthotic (Class-03)	Zain Shami and Dr. Muhammad Nabeel Anwar
25.	19296	Travelers Grater (Class-01)	Mayram Abbas and Khadija Zia
26.	19297	Chashni (Class-01)	Sabah Zaman and Amsal Mumtaz
27.	19298	Citrus Extenso (Class-03)	Bisma Javed and Amsal Mumtaz
28.	19299	Wedge Press (Class-01)	Hassan Faraz and Amsal Mumtaz
29.	19300	Sifter (Class-01)	Fatima Sohail and Amsal Mumtaz
30.	19301	IPVG Configrations/12	M/S IPVG Technical Trading as Ms. Muniza Irshad
19/04/2018			
31.	19302	Rubber (Class-03)	M/S Dollar Industries
20/04/2018			
32.	19303	Plastic Bottle (Class-03)	Jawad Khalid Laghari, Sole Proprietor, Pakistani National, trading as White Horse Oil Industry

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
17/04/2018			
1.	18586	Razor Handle (Class-03)	DORCO Co., LTD.
2.	18186	Gas Valve (Class-01)	M/s. Master Valve
3.	18056	Plastic Drum (Class-03)	Alka (Pvt) Limited
19/04/2018			
4.	18764	PEN (Class-03)	M/S Dollar Industries
5.	17960	Sole (Class-03)	Service Sales Corporation (Private) Limited
6.	18762	PEN (Class-03)	M/S Dollar Industries
7.	18763	PEN (Class-03)	M/S Dollar Industries
8.	18468	3D Model-New Mercrobe No.2 (Class-12)	Merck KGaA
9.	18469	3D Model-Merck_Msep-1_Graustufen (Class-12)	Merck KGaA
10.	18470	3D Model_Merck_Msep-2_Graustufen (Class-12)	Merck KGaA
11.	18471	3D Model-New Mercrobe No.1 (Class-12)	Merck KGaA
12.	18472	3D Model-New Mercrobe No.3 (Class-12)	Merck KGaA
13.	18473	3D Model-New Mercrobe No.4 (Class-12)	Merck KGaA
14.	18474	3D Model-New Mercrobe No.5 (Class-12)	Merck KGaA
15.	18475	3D Model-New Mercrobe No.6 (Class-12)	Merck KGaA
16.	18476	3D Model-New Mercrobe No.7 (Class-12)	Merck KGaA
17.	18477	3D Model-New Mercrobe No.8 (Class-12)	Merck KGaA
18.	18478	3D Model-New Mercrobe No.9 (Class-12)	Merck KGaA

19.	18479	3D Model-New Mercrobe No.10 (Class-12)	Merck KGaA
20.	17313	Mobile Phone (Class-03)	Digicom Trading (Pvt) Limited
21.	18764	PEN (Class-03)	M/S Dollar Industries

(Dr. Muhammad Fayyaz Ahmad)
Controller of Patents
& Registrar of Designs
Ph: 99230591